title: Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.
abstract: In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.
authors.affiliation: Unidade de Cuidados Intensivos Polivalente, Hospital São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, EPE, Estrada do Forte do Alto do Duque, 1449-005 Lisboa, Portugal. povoap@netcabo.pt
authors.forename: Pedro
authors.initials: P
authors.lastname: Póvoa
authors.forename: João
authors.initials: J
authors.lastname: Gonçalves-Pereira
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D058387:Candidemia / Q000188:drug therapy* / Q000453:epidemiology; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use; D005656:Fungal Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000453:epidemiology; D009503:Neutropenia; D017410:Practice Guidelines as Topic / Q000592:standards*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D000666:Amphotericin B; D015725:Fluconazole; C007572:echinocandin B